(Q37678656)

21 August 2017

1 reference

title

Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions (English)

1 reference

21 August 2017

Platelet Adenosine Diphosphate P2Y12 Receptor Antagonism: Benefits and Limitations of Current Treatment Strategies and Future Directions (English)

0 references

1

Dominick J Angiolillo

1 reference

21 August 2017

1

Dominick J. Angiolillo

0 references

author name string

José Luis Ferreiro

series ordinal

2

1 reference

21 August 2017

publication date

1 January 2010

1 reference

Revista Española de Cardiología

21 August 2017

January 2010

0 references

published in

1 reference

21 August 2017

volume

63

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

60-76

1 reference

Atherothrombosis and high-risk plaque: part I: evolving concepts

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Platelet activation and atherothrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Coronary atherothrombotic disease: progress in antiplatelet therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Low-dose aspirin for the prevention of atherothrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Clopidogrel response variability: current status and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Nucleotide receptor signaling in platelets

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Guías de Práctica Clínica sobre intervencionismo coronario percutáneo

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Platelet function assessment to predict outcomes after coronary interventions: hype or hope?

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angiop

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platele

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Pharmacogenetics in cardiovascular antithrombotic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Impact of P-glycoprotein on clopidogrel absorption

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Genetic determinants of response to clopidogrel and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Cytochrome p-450 polymorphisms and response to clopidogrel

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: Do we need more aggressive dosing regimens in unstable angina?

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Platelet function in clopidogrel-treated patients with acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function — a flow cytometry study

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Clopidogrel-statin interaction: myth or reality?

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Calcium-channel blockers reduce the antiplatelet effect of clopidogrel

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Time response of cytochrome P450 1A2 activity on cessation of heavy smoking

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

The association of cigarette smoking with enhanced platelet inhibition by clopidogrel

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Interaction between cigarette smoking and clinical benefit of clopidogrel

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

1 reference

7 January 2021

Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Ef

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patien

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Coronary stent restenosis in patients treated with cilostazol

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

ADP receptor antagonism: what's in the pipeline?

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Advances in antiplatelet therapy: agents in clinical development

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Pharmacology of emerging novel platelet inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a r

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thro

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Clinical overview of promising nonthienopyridine antiplatelet agents

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Platelet inhibition with cangrelor in patients undergoing PCI.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

Intravenous platelet blockade with cangrelor during PCI.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970010-4

7 January 2021

10.1016/S1885-5857(10)70010-4

Identifiers

DOI

0 references

1 reference